Trial record 1 of 1 for:    NCT01227967
Previous Study | Return to List | Next Study

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (IRC003)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01227967
First received: October 22, 2010
Last updated: August 18, 2014
Last verified: August 2014

October 22, 2010
August 18, 2014
September 2010
September 2014   (final data collection date for primary outcome measure)
Evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups. [ Time Frame: First 50 subjects ] [ Designated as safety issue: No ]
The specific measure used for the primary endpoint will be determined by a pilot study of the first 50 subjects randomized which will evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups.
Not Provided
Complete list of historical versions of study NCT01227967 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study will evaluate the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

Seasonal influenza is responsible for approximately 226,000 excess hospitalizations annually and despite effective antivirals causes significant morbidity and mortality (estimated 24,000-50,000 deaths each year in the United States alone). The influenza virus that emerged in 2009 (A/California/07/2009 H1N1) caused fewer deaths (12,000 flu-related deaths in the U.S) but in contrast to seasonal flu, nearly 90 percent of the deaths with the 2009 H1N1 occurred among people younger than 65 years of age. The CDC has defined an at-risk population that is responsible for the majority of hospitalization and morbidity associated with influenza. This study will evaluate the use of combination antivirals as compared to oseltamivir alone in the treatment of influenza in an at-risk population.

Subjects who meet the CDC definition for being at-risk and that present with an influenza-like illness will be screened for the study. Those subjects with a confirmatory test for influenza (rapid antigen or PCR) will be randomized in a 1:1 manner to receive a blinded study treatment consisting of either the combination of amantadine, oseltamivir, and ribavirin or oseltamivir alone for 5 days. Clinical, virologic, and laboratory assessments on Days 1, 3, 7, 14, and 28 will be used for both safety and efficacy analysis.

Objectives:

- To evaluate the effectiveness of combined treatment with oseltamivir, amantadine, and ribavirin compared with oseltamivir alone for at-risk individuals with confirmed influenza infection.

Eligibility:

- Individuals at least 18 years of age who have one or more medical conditions that may cause complications from influenza, and have developed an influenza-like illness.

Design:

  • Participants will be screened with a physical examination and medical history, along with blood tests and throat swabs to confirm influenza infection.
  • Eligible participants will be randomly assigned to take either oseltamivir alone (the current standard treatment for influenza) or to take oseltamivir, amantadine, and ribavirin. Participants will have additional blood samples and throat swabs taken at the start of the study, and will be shown how to complete a study diary at home.
  • Participants will receive a study medication kit containing the medication to take at home twice a day for 5 days.
  • Participants will return, with the medication kit, to the clinic on days 1 (the first day after the start of the study), 3, 7, 14, and 28. The first visit may take 2 to 3 hours, but each subsequent visit should take approximately 1 to 2 hours. Additional blood samples and throat swabs will be taken at these visits.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Influenza
  • Drug: Amantadine, Ribavirin, Oseltamivir
    One capsule of Oseltamivir 75 mg x 2 - Total dose: 150 mg/day for 5 days; Three capsules of Ribavirin 200 mg for total of 600 mg x 2 - Total dose: 1200 mg/day for 5 days; One capsule of Amantadine 100 mg x 2 Total dose: 200 mg/day for 5 days
  • Drug: Oseltamivir
    75 mg x 2 Total dose: 150 mg/day for 5 days
  • Experimental: Combination Therapy
    Amantadine, Ribavirin, Oseltamivir
    Intervention: Drug: Amantadine, Ribavirin, Oseltamivir
  • Active Comparator: Oseltamivir monotherapy
    Oseltamivir
    Intervention: Drug: Oseltamivir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1200
September 2014
September 2014   (final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:

Enrollment (Screening)

  1. Signed informed consent prior to initiation of any study procedures
  2. Age greater than or equal to 18 years of age
  3. Presence of an underlying medical condition(s) that may increase risk of complications from influenza
  4. History of an influenza-like illness defined as:

    • One or more respiratory symptom (cough, sore throat, or nasal symptoms) AND
    • Either
    • Fever (subjective or documented >38 degrees C) OR
    • 1 or more constitutional symptom (headache, malaise, myalgia, sweats/chills or fatigue)
  5. Onset of illness no more than 96 hours before screening defined as when the subject experienced at least one respiratory symptom, constitutional symptom, or fever
  6. Willingness to have samples stored

Randomization

  1. Signed informed consent
  2. Age greater than or equal to 18 years of age
  3. Presence of a medical condition(s) that have been associated with increased risk of complications from influenza

    • Age 65 years of age or older
    • Asthma
    • Neurological and neuro-developmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury) [though still able to provide informed consent per inclusion criteria #1]
    • Chronic lung disease (such as COPD and cystic fibrosis)
    • Heart disease (such as congenital heart disease, congestive heart failure, and coronary artery disease)
    • Blood disorders (excluding genetic causes of anemia, as noted in the exclusion criteria)
    • Endocrine disorders (such as diabetes mellitus)
    • Kidney disorders
    • Liver disorders
    • Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
    • Weakened immune system due to disease or medication (such as people with HIV/AIDS, or cancer, chronic steroids or other medications causing immune suppression)
    • BMI ≥ 40
  4. Onset of illness no more than 96 hours before screening defined as when the subject experienced at least one respiratory symptom, constitutional symptom, or fever
  5. Positive test for influenza (either rapid antigen or PCR)

    - Results from influenza testing obtained for clinical indications within 12 hours before screening/enrollment may be used if available. Randomization may proceed in cases of discrepant results (one positive and one negative)

  6. One of the following to avoid pregnancy:

    • Females who are able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use at least 2 effective forms of contraception from the date of informed consent through 6 months after the last dose of study drug. At least one of the methods of contraception should be a barrier method
    • Males who have not undergone surgical sterilization and are sexually active with women must agree to use condoms plus have a partner use at least one additional effective form of contraception from the date of informed consent through 6 months after the last dose of study drug
  7. Willingness to have samples stored

EXCLUSION CRITERIA:

(for Enrollment or Randomization)

  1. Women who are pregnant or breast-feeding, and men whose female partner(s) is pregnant
  2. Inability to take oral medication or a history of gastrointestinal malabsorption that would preclude the use of oral medication.
  3. Hemoglobin < 10 g/dL
  4. WBC < 1.5 times 10(9)/L
  5. Neutrophils < 0.75 x 10(9)/L
  6. Platelets < 50 x 10(9)/L
  7. History of genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia
  8. Received more than 2 doses of any antiviral influenza medications since onset of influenza symptoms
  9. Received stavudine (d4T), didanosine (ddI), zidovudine (AZT), or azathioprine within 30 days prior to study entry
  10. Creatinine clearance less than 50 mL/min (estimated by the Cockcroft-Gault equation using serum creatinine)
  11. History of autoimmune hepatitis
  12. Uncompensated liver disease (defined as AST > 3 times site upper limit of normal (ULN), ALT > 3 times ULN, or Direct Bilirubin > 2 times ULN)
  13. Clinical signs of end-stage liver disease including jaundice, coagulopathy, portal hypertension, esophageal varices, ascites, peripheral edema, gastrointestinal bleeding, or encephalopathy
  14. Chronic liver disease categorized as Child-Pugh class C (Child-Pugh score 10-15)
  15. Known hypersensitivity to rimantadine, amantadine, ribavirin, oseltamivir, peramivir, or zanamivir
  16. Received live attenuated virus vaccine (influenza or other) within 3 weeks prior to study entry
  17. Use of any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study entry
Both
18 Years and older
No
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010
United States,   Argentina,   Australia,   Mexico,   Thailand
 
NCT01227967
10-I-0210, 10-I-0210, IRC003
Yes
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: John Beigel, MD Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, Natinal Institutes of Health
Study Chair: John Treanor, MD University of Rochester, School of Medicine and Dentistry
National Institute of Allergy and Infectious Diseases (NIAID)
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP